Chest
-
COPD PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) is being developed for treatment of COPD. This study assessed the efficacy and safety of two twice-daily (BID) FDCs vs monotherapies and placebo. ⋯ Dave Singh: Grant monies (from industry related sources): AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck, Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, GlaxoSmithKline, Chiesi, Boehringer Ingleheim, Roche, Novartis, Cipla, Almirall and Merck Paul Jones: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc. Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Almirall S.A., Consultant fee, speaker bureau, advisory committee, etc.: Forest Laboratories, Inc., Grant monies (from industry related sources): E D Bateman's has received payment from Almirall for participation in clinical trials Stephanie Korn: Consultant fee, speaker bureau, advisory committee, etc.: Almirall Cristina Serra: Employee: Almirall S.A. Eduard Molins: Employee: Almirall S.A. Cynthia Caracta: Employee: Almirall S.A. Esther Garcia Gil: Employee: Almirall S.A. Anne Leselbaum: Employee: Almirall S.A.This abstracts presents the results of a double blind, randomized Phase III trial of a fixed combination of two products, each of which are approved as monotherapies for the treatment of COPD.
-
Respiratory InfectionsSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: INTRODUCTION Elevated ADA levels in pleural fluid are highly suggestive of pleural tuberculosis. In fact, values above 35UL in our practice present levels of sensitivity and specificity > 90%. However, sometimes we find very high levels of ADA Pleural uncommon for tuberculosis. Is there an upper limit level of ADA to justify the possibility of another process? ⋯ The following authors have nothing to disclose: Patricia Lazo Meneses, Esteban Perez Rodriguez, Carolina Gotera, Jonathan Cámara Fernández, Deisy Barrios Barreto, Salvador Diaz Lobato, Sagrario Mayoralas Alises, Eva Mañas Baena, Rosa Mirambeaux VillalonaNo Product/Research Disclosure Information.
-
ILD Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Non Specific Interstitial Pneumonia (NSIP) is a type of diffuse parenchymal lung disease with distinct clinico-pathologic features. It typically presents with progressive dyspnea and cough that develop sub-acutely. There are few reports of patients presenting with an acute exacerbation (AE) of NSIP at the time of initial diagnosis. ⋯ It has been well described that patients with Idiopathic Pulmonary Fibrosis may experience AE's and recently AE's have been described among patients with NSIP.1CONCLUSIONS: We believe our case represents an AE as the initial presentation of NSIP, which to our knowledge has not been previously described in the absence of prior imaging consistent with possible NSIP. Additionally our patient's accelerated clinical and radiographic improvement is unique.Reference #1: Park N, Kim S, et al. Acute Exacerbation of Interstitial Pneumonia Other Than IPF. Chest 2007: 132; 214-220DISCLOSURE: The following authors have nothing to disclose: Michael Colancecco, Andres SosaNo Product/Research Disclosure Information.
-
Multiple questionnaires have been used to predict the diagnosis of OSA. Such models typically have multiple questions requiring cumulative scoring for interpretation. We wanted to determine whether a simple two-part questionnaire has predictive value in the pretest clinical evaluation for OSA. ⋯ Among patients referred to a sleep disorders clinic, a positive response to being elbowed/poked for apneic spells significantly improves the pretest prediction of OSA.
-
Comparative Study
Radiation risks in lung cancer screening programs: a comparison with nuclear industry workers and atomic bomb survivors.
The National Lung Cancer Screening Trial (NLST) demonstrated that screening with low-dose CT (LDCT) scan reduced lung cancer and overall mortality by 20% and 7%, respectively. The LDCT scanning involves an approximate 2-mSv dose, whereas full-chest CT scanning, the major diagnostic study used to follow up nodules, may involve a dose of 8 mSv. Radiation associated with CT scanning and other diagnostic studies to follow up nodules may present an independent risk of lung cancer. ⋯ This assessment suggests that long-term (20-30 years) LDCT screening programs are associated with nontrivial cumulative radiation doses. Current lung cancer screening protocols, if conducted over 20- to 30-year periods, can independently increase the risk of lung cancer beyond cigarette smoking as a result of cumulative radiation exposure. Radiation exposures from LDCT screening and follow-up diagnostic procedures exceed lifetime radiation exposures among nuclear power workers and atomic bomb survivors.